SEC Form 10-Q filed by Whitehawk Therapeutics Inc.
$WHWK
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and
MORRISTOWN, N.J., Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City, NY on December 3, 2025, at 12:30 PM ET. A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics Whitehawk
MORRISTOWN, N.J., Nov. 11, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that Dave Lennon, PhD, President and CEO, will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 11:30 AM GMT. A live webcast of the presentation can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event. About Whitehawk Therapeutics Whitehawk Therapeutics is an oncology therapeutics compan
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
3 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer (CMO). Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy. "I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and